ILCA 2024 | Dr. Lin Zhang: New Perspectives in Liver Cancer Treatment – The Impact of Immune Microenvironment on SIRT Efficacy

ILCA 2024 | Dr. Lin Zhang: New Perspectives in Liver Cancer Treatment – The Impact of Immune Microenvironment on SIRT Efficacy

2024.11.08
Selective Internal Radiation Therapy (SIRT) is a validated treatment for liver cancer, yet the influence of the immune microenvironment on treatment response and survival remains unclear. At the 18th International Liver Cancer Association (ILCA) Annual Conference, a recent study shed light on the complex relationship between the immune microenvironment in liver cancer patients prior to SIRT and its impact on treatment response and survival. Oncology Frontier invited Dr. Lin Zhang, from the Hepatobiliary Interventional Radiology Department at Beijing Tsinghua Changgung Hospital, to provide an expert analysis. With a detailed breakdown of the data and expert interpretation, this study offers valuable insights into the role of the local immune state in liver cancer treatment, paving the way for personalized and combination therapy strategies.
Dr. Jie Xu: Advancing Empirical Treatment Strategies for Febrile Neutropenia

Dr. Jie Xu: Advancing Empirical Treatment Strategies for Febrile Neutropenia

2024.11.08
Febrile neutropenia is a significant concern among immunocompromised patients due to the high infection-related mortality if left untreated. At the recent 4th Shanghai Symposium on Clinical Application of Autologous Hematopoietic Stem Cell Transplantation, Dr. Jie Xu of Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, discussed new empirical treatment approaches. This article consolidates the key points from her presentation.
IHPBA President | Prof. René Adam and Academician Xiaoping Chen：Strengthening Friendships and Enhancing Cooperation – Expanding the Vision of the International Hepato-Pancreato-Biliary Association (IHPBA) in China

IHPBA President | Prof. René Adam and Academician Xiaoping Chen：Strengthening Friendships and Enhancing Cooperation – Expanding the Vision of the International Hepato-Pancreato-Biliary Association (IHPBA) in China

2024.11.08
From October 25 to 28, 2024, Wuhan hosted an enriching academic exchange – the 9th Academic Symposium of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (CCIHPBA), alongside the symposium commemorating the 110th birth anniversary of Academician Fazu Qiu and a tribute to Academician Yunyi Liu. Oncology Frontier, invited Prof. René Adam, current President of IHPBA from AP-HP Paul Brousse Hospital in Paris, France, and Academician Xiaoping Chen, President of the CCIHPBA from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, to share insights on IHPBA's mission and the establishment and development of its Chinese chapter.
The 2024 Jiangsu Hematology Physicians Association Conference Highlights Advancements in Standardized Diagnosis and Treatment of Hematologic diseases

The 2024 Jiangsu Hematology Physicians Association Conference Highlights Advancements in Standardized Diagnosis and Treatment of Hematologic diseases

2024.11.07
From October 18 to 20, 2024, the 2024 Jiangsu Hematology Physicians Association Academic Conference was held in Taizhou, Jiangsu Province, focusing on the standardized diagnosis and treatment of hematologic diseases. Organized by the Jiangsu Hematology Physicians Association and hosted by the Affiliated Taizhou People’s Hospital of Nanjing Medical University and The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), the conference provided a high-level academic exchange platform. Hematology Frontier invited Dr. Jianyong Li, Chairman of the conference and a distinguished expert from Jiangsu Provincial People’s Hospital, to share his insights on the event’s key highlights and discuss the current and future directions of hematology in China.
ESMO 2024| Dr. Zhen Cai: Progress in Immunotherapy for Multiple Myeloma and New Perspectives on MRD Detection

ESMO 2024| Dr. Zhen Cai: Progress in Immunotherapy for Multiple Myeloma and New Perspectives on MRD Detection

2024.11.07
CAR-T therapy and bispecific antibodies, two innovative immunotherapies, have shown significant efficacy in patients with relapsed/refractory multiple myeloma (RRMM). But how do these two therapies compare in clinical practice? Minimal Residual Disease (MRD) detection is an important tool for evaluating treatment response and prognosis in multiple myeloma (MM), but its application in clinical settings is still limited. How can MRD use be further promoted? At the recent European Society for Medical Oncology (ESMO) Congress 2024, two pivotal studies delved into these questions, sparking widespread attention. This article features insights from Dr. Zhen Cai of The First Affiliated Hospital of Zhejiang University School of Medicine on these studies.
Dr. Rong Fu: Dedicated Exploration – New Insights and Treatments in Aplastic Anemia

Dr. Rong Fu: Dedicated Exploration – New Insights and Treatments in Aplastic Anemia

2024.11.07
Aplastic Anemia (AA), a type of bone marrow failure syndrome, is challenging to treat. While hematopoietic stem cell transplantation (HSCT) may offer a cure, it is hindered by donor availability and high risk. Medical treatments provide symptom relief but with limited efficacy and potential for relapse. At the recent 18th Annual Chinese Society of Hematology Conference, Dr. Rong Fu from Tianjin Medical University General Hospital presented valuable insights into immunosuppressive therapy (IST) for AA. Following the conference, Hematology Frontier invited Professor Fu to discuss China’s AA prevalence, diagnostic and treatment advancements, current IST options, and future management strategies.
Professor Eolia Brissot: The Deepening and Expansion of Blinatumomab in Non-Chemotherapy Strategies for Acute Lymphoblastic Leukemia

Professor Eolia Brissot: The Deepening and Expansion of Blinatumomab in Non-Chemotherapy Strategies for Acute Lymphoblastic Leukemia

2024.11.07
The 11th Sino-French Hematology Academic Conference of the Chinese Medical Doctor Association attracted hundreds of domestic and international authoritative experts and scholars in the field of hematology to gather together. During the conference, "Hematology Frontier" specially invited Professor Eolia Brissot from Hôpital Saint-Antoine in Paris to share the latest explorations of non-chemotherapy strategies in the treatment of acute lymphoblastic leukemia.